• Nanobiotix reported that Johnson & Johnson presented Part 1 data at ESTRO 2026 from the CONVERGE randomized Phase 2 study of JNJ-1900 (NBTXR3) in stage III inoperable non-small cell lung cancer.
• The early readout indicated the intratumoral or intranodal injection approach was feasible, with no new safety concerns flagged in the update.
• Investigators also observed encouraging tumor shrinkage signals in patients who completed the full regimen, with no cases of disease worsening reported in that cohort.
• The company framed the deepening responses over time as supportive of potential durability, positioning the program as a possible enhancement to standard chemoradiotherapy followed by durvalumab.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanobiotix SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-003496), on May 18, 2026, and is solely responsible for the information contained therein.